Recent Updates
Recently added Catalysts
ELAN Negative Sentiment Score: 20/100

ELANCO ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against Elanco Animal Health Incorporated in the U.S. District Court for the District of Maryland. The lawsuit, initiated by Bragar Eagel & Squire, P.C., claims that the company made false and misleading statements regarding its business and prospects during the specified class period. Allegations include the safety concerns over Zenrelia and doubts about timely approvals for products including Credelio Quattro. Investors affected by these claims are encouraged to participate in the lawsuit and contact the firm for more information.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Elanco due to misleading statements.
  • Allegations suggest Zenrelia is less safe than previously claimed.
  • Company unlikely to meet timelines for U.S. approval of key products.
  • Public statements about the company's financial prospects were misleading.

Full Press Release Details

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia was less safe than the Company had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (3) accordingly, the Company's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Elanco shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the class action lawsuit against Elanco about?

The lawsuit claims Elanco made misleading statements about its business and product safety.

Who can participate in the Elanco class action lawsuit?

All individuals or entities that purchased Elanco securities between November 2023 and June 2024 can participate.

When is the deadline to apply as lead plaintiff in the lawsuit?

The deadline to apply is December 6, 2024.

Which products are involved in the lawsuit against Elanco?

The lawsuit concerns inaccuracies related to Zenrelia and Credelio Quattro.

How can investors contact Bragar Eagel & Squire for inquiries?

Investors can reach out via email at investigations@bespc.com or call 212-355-4648.

Last updated: Nov 7, 2024